REG - Haleon PLC - Total Voting Rights and Capital

HALEONAnnouncement

Today 09:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250501:nRSA0119Ha&default-theme=true

RNS Number : 0119H  Haleon PLC  01 May 2025

 

 

Haleon plc: Total Voting Rights and Capital

 

1 May 2025: As at 30 April 2025 the total number of shares issued by Haleon
plc ("Haleon" or the "Company") is 9,020,990,697 ordinary shares of £0.01
each, of which 4,080,205 are held as treasury shares.

 

Therefore, the number of ordinary shares with voting rights is 9,016,910,492
and this figure should be used by shareholders (and others with notification
obligations) as the denominator for the calculation by which they will
determine if they are required to notify their interest in, or a change to
their interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.

 

Notifiable interests in Haleon may be sent to: company.secretary@haleon.com
(mailto:company.secretary@haleon.com)

 

Amanda Mellor

Company Secretary

 

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans five major categories - Oral Health, Pain Relief, Respiratory Health,
Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu,
Otrivin, Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRUASNRVKUVRRR